Johnson & Johnson's innovative medicines division shows promise with expected revenues of $57bn by 2025. See more about JNJ ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson MedTech (NYSE: JNJ) today announced the first completed commercial case with its Varipulse platform in ...

RBC Capital raised the firm’s price target on Johnson & Johnson to $181 from $178 and keeps an Outperform rating on the ...

Johnson & Johnson has been a stalwart dividend stock over the years because it has maintained a healthy financial profile, ...

The FDA’s Suzanne Schwartz said at The Medtech Conference that addressing legacy devices is a “work in progress” and a problem that regulators and industry need to work on together.

The article " Johnson & Johnson Stock: Setting the Stage for 2025 Highs " first appeared on MarketBeat.

Here are eight key developments from spine and orthopedic devicemakers since Oct. 9. 1. Johnson & Johnson MedTech began the first phase of launching its Volt Variable Angle Optimized Locking ...

The CIO50 Awards program celebrates the achievements of the top senior technology and digital executives in Australia who are ...

Carlos Tavares, Chief Executive Officer of Stellantis, poses in front of a Citroen C5 Aircross concept car on media day at the 2024 Paris Auto Show in Paris, France, October 14, 2024. REUTERS ...